Adj AProf Danny Soon

Adj A/Prof Danny Soon

Adj A/Prof Danny Soon is Chief Executive Officer at the Consortium for Clinical Research and Innovation, Singapore (CRIS) and concurrent Executive Director at the Singapore Clinical Research Institute (SCRI). As the inaugural CEO of CRIS, A/Prof Soon has the responsibility of bringing together six research programmes and platforms under the auspices of CRIS, promulgating synergies and strategies, building corporate functions to service the entire entity. A/Prof Soon was previously the Interim Executive Director of Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) from 1 September 2022 to 28 February 2025.

A/Prof Soon was previously the Executive Director of Biomedical Research Council (BMRC) in A*STAR. His team in BMRC was responsible for incepting and coordinating efforts and programmes in drug development, precision medicine, medical technology and biomanufacturing. A/Prof Soon also held the role of founding and Acting CEO of the Experimental Biotherapeutics Centre.

A/Prof Soon has long experience in drug development, having worked at Eli Lilly and Company for 15 years, where he headed up the Lilly-NUS Centre for Clinical Pharmacology (LNUS). As the Managing Director and Principal Investigator, A/Prof Soon had responsibility and oversight for all clinical Phase 1 studies conducted and operations in the unit. Studies conducted included first-in-human studies, biomarker development work, human physiology investigations and pivotal registration PK studies, in neuroscience, diabetes, musculoskeletal and cardiovascular therapeutic areas.